uproleselan

Also Known As:

(2S)-2-(((2R,3R,4R,5R,6R)-3-acetamido-2-(((1R,2R,3S,5R)-5-((2-(4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxaoctatriacontanamido)ethyl)carbamoyl)-3-ethyl-2-(alpha-L-galactopyranosyloxy)cyclohexyl)oxy)-5-hydroxy-6-(hydroxymethyl)oxan-4-yl)oxy)-3-cyc; ABI-701; ABI701; GMI-1271; GMI-1271 free acid; GMI-1271 sodium; GMI-1687; Sodium (2S)-2-(((2R,3R,4R,5R,6R)-3-acetamido-2-(((1R,2R,3S,5R)-5-((2-(4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxaoctatriacontanamido)ethyl)carbamoyl)-3-ethyl-2-(alpha-L-galactopyranosyloxy)cyclohexyl)oxy)-5-hydroxy-6-(hydroxymethyl)oxan-4-yl)oxy; uproleselan sodium

Networked: 8 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Magnani, John L: 4 articles (01/2022 - 01/2017)
2.	Hawley, Angela: 3 articles (01/2022 - 01/2020)
3.	Myers, Daniel D: 3 articles (01/2022 - 01/2017)
4.	Sood, Suman: 3 articles (01/2022 - 01/2017)
5.	Adili, Reheman: 2 articles (01/2022 - 01/2020)
6.	Crego, Kiley: 2 articles (01/2022 - 01/2020)
7.	Dunivant, Veronica: 2 articles (01/2022 - 01/2020)
8.	Durham, Laura: 2 articles (01/2022 - 01/2020)
9.	Holinstat, Michael: 2 articles (01/2022 - 01/2020)
10.	Lester, Patrick: 2 articles (01/2022 - 01/2020)

Related Diseases

1.	Mucositis 01/01/2022 - "The addition of uproleselan to chemotherapy was well tolerated, with high remission rates, low induction mortality, and low rates of mucositis, providing a strong rationale for phase 3 randomized confirmatory studies. " 01/18/2021 - "Several preclinical and clinical studies summarized herein demonstrate that uproleselan has favorable safety and pharmacokinetics and is a tumor microenvironment-disrupting agent that improves the efficacy of chemotherapy, reduces side effects such as neutropenia, intestinal mucositis and infections, and extends overall survival. "
2.	Neutropenia 01/18/2021 - "Several preclinical and clinical studies summarized herein demonstrate that uproleselan has favorable safety and pharmacokinetics and is a tumor microenvironment-disrupting agent that improves the efficacy of chemotherapy, reduces side effects such as neutropenia, intestinal mucositis and infections, and extends overall survival. "
3.	Infections 01/18/2021 - "Several preclinical and clinical studies summarized herein demonstrate that uproleselan has favorable safety and pharmacokinetics and is a tumor microenvironment-disrupting agent that improves the efficacy of chemotherapy, reduces side effects such as neutropenia, intestinal mucositis and infections, and extends overall survival. "
4.	Hemorrhage 02/01/2020 - "GMI-1271, a potent small-molecule E-selectin antagonist, has been shown in mouse models to decrease thrombus burden with a low risk of bleeding. " 01/01/2017 - "E-selectin inhibition with GMI-1271 decreases venous thrombosis without profoundly affecting tail vein bleeding in a mouse model." 01/01/2022 - "This study evaluated E-selectin inhibition with GMI-1271 (Uproleselan [GMI]) alone and in combination with the standard of care low-molecular-weight heparin (LMWH) to improve vein recanalization, decrease vein wall inflammation and protect against adverse bleeding in a primate model. "
5.	Inflammation (Inflammations) 01/01/2020 - "GMI-1271 significantly decreased vein wall inflammation by MRV with gadolinium vein wall enhancement vs control also on day 14 (P < .0001) and day 21 (P < .0001). " 01/01/2022 - "This study evaluated E-selectin inhibition with GMI-1271 (Uproleselan [GMI]) alone and in combination with the standard of care low-molecular-weight heparin (LMWH) to improve vein recanalization, decrease vein wall inflammation and protect against adverse bleeding in a primate model. "

Related Drugs and Biologics

1.	uproleselan
2.	E-Selectin
3.	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
4.	Mitoxantrone (Novantrone)
5.	Etoposide (VP 16)
6.	Cytarabine (Cytosar-U)
7.	Enoxaparin (Lovenox)
8.	Cell Adhesion Molecules
9.	Gadolinium
10.	Imatinib Mesylate (Gleevec)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)

HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Application Error

An application error has occurred and our support engineers have been notified.

Please use the browser "Back" button and try your operation again.

OR if the error persists and you require an email response
please contact us at "cs at curehunter.com":

Your request
The circumstances of the error
Your login id/nickname or email

Return to Top Page